Document Detail

Intracoronary injection of in situ forming alginate hydrogel reverses left ventricular remodeling after myocardial infarction in Swine.
MedLine Citation:
PMID:  19729119     Owner:  NLM     Status:  MEDLINE    
OBJECTIVES: This study sought to determine whether alginate biomaterial can be delivered effectively into the infarcted myocardium by intracoronary injection to prevent left ventricular (LV) remodeling early after myocardial infarction (MI). BACKGROUND: Although injectable biomaterials can improve infarct healing and repair, the feasibility and effectiveness of intracoronary injection have not been studied. METHODS: We prepared a calcium cross-linked alginate solution that undergoes liquid to gel phase transition after deposition in infarcted myocardium. Anterior MI was induced in swine by transient balloon occlusion of left anterior descending coronary artery. At 4 days after MI, either alginate solution (2 or 4 ml) or saline was injected selectively into the infarct-related coronary artery. An additional group (n = 19) was treated with incremental volumes of biomaterial (1, 2, and 4 ml) or 2 ml saline and underwent serial echocardiography studies. RESULTS: Examination of hearts harvested after injection showed that the alginate crossed the infarcted leaky vessels and was deposited as hydrogel in the infarcted tissue. At 60 days, control swine experienced an increase in left ventricular (LV) diastolic area by 44%, LV systolic area by 45%, and LV mass by 35%. In contrast, intracoronary injection of alginate (2 and 4 ml) prevented and even reversed LV enlargement (p < 0.01). Post-mortem analysis showed that the biomaterial (2 ml) increased scar thickness by 53% compared with control (2.9 +/- 0.1 mm vs. 1.9 +/- 0.3 mm; p < 0.01) and was replaced by myofibroblasts and collagen. CONCLUSIONS: Intracoronary injection of alginate biomaterial is feasible, safe, and effective. Our findings suggest a new percutaneous intervention to improve infarct repair and prevent adverse remodeling after reperfused MI.
Jonathan Leor; Shmuel Tuvia; Victor Guetta; Ferenc Manczur; David Castel; Udi Willenz; Ors Petneházy; Natali Landa; Micha S Feinberg; Eli Konen; Orly Goitein; Orna Tsur-Gang; Mazal Shaul; Lea Klapper; Smadar Cohen
Related Documents :
8287879 - Regional uptake of iodine-125-metaiodobenzylguanidine in the rat heart.
20029739 - Echocardiography of the right ventricle in athlete's heart and hearts of normal size co...
9185639 - Preoperative left ventricular peak systolic pressure/end-systolic volume ratio and func...
18724039 - Surgical removal of left ventricular ball-like thrombus following large transmural acut...
19892059 - Optimization of the interventricular delay in cardiac resynchronization therapy using t...
11236839 - Coronary artery disease modifies left ventricular remodelling due to heavy alcohol cons...
20164089 - Prognostic value of exercise echocardiography in patients with atrial fibrillation.
16382289 - Effect of catheter-based transendocardial delivery of stromal cell-derived factor 1alph...
22897649 - Unipolar and bipolar electrogram characteristics predict exit block during pulmonary ve...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of the American College of Cardiology     Volume:  54     ISSN:  1558-3597     ISO Abbreviation:  J. Am. Coll. Cardiol.     Publication Date:  2009 Sep 
Date Detail:
Created Date:  2009-09-04     Completed Date:  2009-09-29     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8301365     Medline TA:  J Am Coll Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1014-23     Citation Subset:  AIM; IM    
Neufeld Cardiac Research Institute, Sheba Medical Center, Tel-Aviv University, Tel-Hashomer 52621, Israel.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Alginates / administration & dosage*
Biocompatible Materials / administration & dosage*
Disease Models, Animal
Feasibility Studies
Glucuronic Acid / administration & dosage
Heart Rate
Hexuronic Acids / administration & dosage
Hydrogel / administration & dosage*
Injections, Intralesional
Myocardial Infarction / complications*,  pathology*,  physiopathology
Stroke Volume
Ventricular Remodeling / drug effects*
Reg. No./Substance:
0/Alginates; 0/Biocompatible Materials; 0/Hexuronic Acids; 25852-47-5/Hydrogel; 576-37-4/Glucuronic Acid; 9005-32-7/alginic acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Usefulness of the valvuloarterial impedance to predict adverse outcome in asymptomatic aortic stenos...
Next Document:  A human atrial natriuretic peptide gene mutation reveals a novel peptide with enhanced blood pressur...